⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329850 | 0.75 | — | — | |
| Iodide SCHEMBL31261479 | 0.73 | — | — | |
| SCHEMBL6033539 | 0.73 | — | — | |
| SCHEMBL1551404 | 0.73 | — | — | |
| SCHEMBL24740907 | 0.72 | TAS2R38 (0.31) | — | |
| SCHEMBL9167622 | 0.71 | — | — | |
| SCHEMBL5353897 | 0.71 | — | — | |
| SCHEMBL24069363 | 0.71 | — | — | |
| SCHEMBL6810646 | 0.71 | — | — | |
| SCHEMBL11148579 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | claimed |
| EP-4688790-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-01-29 | — | — | US | claimed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | claimed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | claimed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | claimed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-118852330-A | RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024211712-A1 | CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-10 | — | — | WO | claimed |
| CN-117616031-A | RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117597354-A | Method for inhibiting RAS | 综合医院公司 | 2024-02-23 | — | — | CN | claimed |
| EP-4320143-A1 | METHODS FOR INHIBITING RAS | The General Hospital Corporation (US) | 2024-02-14 | — | — | EP | claimed |
| CN-115873020-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | claimed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | claimed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | claimed |
| WO-2022212894-A1 | METHODS FOR INHIBITING RAS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | claimed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | claimed |